drugset / Trial / NCT00135720

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

NCT00135720

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to find out about the effectiveness and the safety of an investigational drug called etanercept (Enbrel) to treat pemphigus vulgaris. Pemphigus vulgaris is a potentially life threatening blistering condition that currently has no cure. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA) to treat a particular condition or disease. Etanercept has been approved by the FDA to treat rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriasis, but not pemphigus vulgaris.

Timeline

Start
2004-06
Primary completion
Completion
2007-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic

Indications